Nathan TM Huneke

Dr. Nathan TM Huneke

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NHNathan TM Huneke
Nathan TM Huneke
CBChristopher A. Brown
Christopher A. Brown
EBEdward Burford
Edward Burford
AWAlison Watson
Alison Watson
NTNelson J. Trujillo-Barreto
Nelson J. Trujillo-Barreto
AJAnthony K. P. Jones
Anthony K. P. Jones
The lack of clear understanding of the pathophysiology of chronic pain could explain why we currently have only a few effective treatments. Understanding how pain relief is realised during placebo analgesia could help develop improved treatments for chronic pain. Here, we tested whether experimental placebo analgesia was associated with altered resting-state cortical activity in the alpha frequency band of the electroencephalogram (EEG). Alpha oscillations have been shown to be influenced by top-down processes, which are thought to underpin the placebo response. Seventy-three healthy volunteers, split into placebo or control groups, took part in a well-established experimental placebo procedure involving treatment with a sham analgesic cream. We recorded ongoing (resting) EEG activity before, during, and after the sham treatment. We show that resting alpha activity is modified by placebo analgesia. Post-treatment, alpha activity increased significantly in the placebo group only (p < 0.001). Source analysis suggested that this alpha activity might have been generated in medial components of the pain network, including dorsal anterior cingulate cortex, medial prefrontal cortex, and left insula. These changes are consistent with a cognitive state of pain expectancy, a key driver of the placebo analgesic response. The manipulation of alpha activity may therefore present an exciting avenue for the development of treatments that directly alter endogenous processes to better control pain.

24 June 2024 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
NHNathan TM Huneke
Nathan TM Huneke
JAJay Amin
Jay Amin
DBDavid S. Baldwin
David S. Baldwin
ABAlessio Bellato
Alessio Bellato
VBValerie Brandt
Valerie Brandt
SCSamuele Cortese
Samuele Cortese
There is a growing literature exploring the placebo response within specific mental disorders, but no overarching quantitative synthesis of this research has analyzed evidence across mental disorders. We carried out an umbrella review of meta-analyses of randomized controlled trials (RCTs) of biological treatments (pharmacotherapy or neurostimulation) for mental disorders. We explored whether placebo effect size differs across distinct disorders, and the correlates of increased placebo effects. Based on a pre-registered protocol, we searched Medline, PsycInfo, EMBASE, and Web of Knowledge up to 23.10.2022 for systematic reviews and/or meta-analyses reporting placebo effect sizes in psychopharmacological or neurostimulation RCTs. Twenty meta-analyses, summarising 1,691 RCTs involving 261,730 patients, were included. Placebo effect size varied, and was large in alcohol use disorder (g = 0.90, 95% CI [0.70, 1.09]), depression (g = 1.10, 95% CI [1.06, 1.15]), restless legs syndrome (g = 1.41, 95% CI [1.25, 1.56]), and generalized anxiety disorder (d = 1.85, 95% CI [1.61, 2.09]). Placebo effect size was small-to-medium in obsessive-compulsive disorder (d = 0.32, 95% CI [0.22, 0.41]), primary insomnia (g = 0.35, 95% CI [0.28, 0.42]), and schizophrenia spectrum disorders (standardized mean change = 0.33, 95% CI [0.22, 0.44]). Correlates of larger placebo response in multiple mental disorders included later publication year (opposite finding for ADHD), younger age, more trial sites, larger sample size, increased baseline severity, and larger active treatment effect size. Most (18 of 20) meta-analyses were judged ‘low’ quality as per AMSTAR-2. Placebo effect sizes varied substantially across mental disorders. Future research should explore the sources of this variation. We identified important gaps in the literature, with no eligible systematic reviews/meta-analyses of placebo response in stress-related disorders, eating disorders, behavioural addictions, or bipolar mania.

16 March 2017 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
DBDavid S. Baldwin
David S. Baldwin
RHRuihua Hou
Ruihua Hou
RGRobert Gordon
Robert Gordon
NHNathan TM Huneke
Nathan TM Huneke
MGMatthew Garner
Matthew Garner

16 October 2018 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
AWAnnabel E. L. Walsh
Annabel E. L. Walsh
NHNathan TM Huneke
Nathan TM Huneke
RBRandi Brown
Randi Brown
MBMichael Browning
Michael Browning
PCPhil Cowen
Phil Cowen
CHCatherine J. Harmer
Catherine J. Harmer
Background: Previous research indicates that antidepressants can restore the balance between negative and positive emotional processing early in treatment, indicating a role of this effect in later mood improvement. However, less is known about the effect of antidepressants on reward processing despite the potential relevance to the treatment of anhedonia. In this study, we investigated the effects of an acute dose of the atypical antidepressant (dual dopamine and noradrenaline reuptake inhibitor) bupropion on behavioral measures of emotional and reward processing in healthy volunteers. Methods: Forty healthy participants were randomly allocated to double-blind intervention with either an acute dose of bupropion or placebo prior to performing the Emotional Test Battery (ETB) and a probabilistic instrumental learning task. Results: Acute bupropion significantly increased the recognition of ambiguous faces as happy, decreased response bias toward sad faces and reduced attentional vigilance for fearful faces compared to placebo. Bupropion also reduced negative bias compared to placebo in the emotional recognition memory task (EMEM). There was no evidence that bupropion enhanced reward processing or learning. Instead, bupropion was associated with reduced likelihood to choose high-probability wins and increased score on a subjective measure of anhedonia. Conclusions: Whilst acute bupropion decreases negative and increases positive emotional processing, it has an adverse effect on reward processing. There seems to be a dissociation of the acute effects of bupropion on positive emotional processing and reward processing, which may have clinical implications for anhedonia early in treatment.

31 August 2012 in Current Rheumatology Reports
Verified
Journal Article
Closed access
PDF file
AJAnthony K. P. Jones
Anthony K. P. Jones
NHNathan TM Huneke
Nathan TM Huneke
DLDonna M. Lloyd
Donna M. Lloyd
CBChris A. Brown
Chris A. Brown
AWAlison Watson
Alison Watson

1 January 2020 in Psychological Medicine
Verified
Journal Article
Open access
PDF file
NHNathan TM Huneke
Nathan TM Huneke
NWNic van der Wee
Nic van der Wee
MGMatthew Garner
Matthew Garner
DBDavid S. Baldwin
David S. Baldwin
Placebos are not inert, but exert measurable biological effects. The placebo response in psychiatric illness is important and clinically relevant, but remains poorly understood. In this paper, we review current knowledge about the placebo response in psychiatric medicine and identify research directions for the future. We argue that more research is needed into the placebo response in psychiatric medicine for three broad reasons. First, awareness of factors that cause placebo response, for whom, and when, within clinical trials will allow us to better evidence efficacy of new treatments. Second, by understanding how placebo mechanisms operate in the clinic, we can take advantage of these to optimise the effects of current treatments. Finally, exploring the biological mechanisms of placebo effects might reveal tractable targets for novel treatment development.